DK1589031T3 - Fremstillingaf polyketider og andre naturlige produkter - Google Patents

Fremstillingaf polyketider og andre naturlige produkter

Info

Publication number
DK1589031T3
DK1589031T3 DK05075774T DK05075774T DK1589031T3 DK 1589031 T3 DK1589031 T3 DK 1589031T3 DK 05075774 T DK05075774 T DK 05075774T DK 05075774 T DK05075774 T DK 05075774T DK 1589031 T3 DK1589031 T3 DK 1589031T3
Authority
DK
Denmark
Prior art keywords
compounds
fkbp
polyketides
natural products
analogues
Prior art date
Application number
DK05075774T
Other languages
Danish (da)
English (en)
Inventor
Matthew Alan Gregory
Sabine Gaisser
Hrvoje Petkovic
Steven Moss
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0216509A external-priority patent/GB0216509D0/en
Priority claimed from GB0224922A external-priority patent/GB0224922D0/en
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Application granted granted Critical
Publication of DK1589031T3 publication Critical patent/DK1589031T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/76Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK05075774T 2002-07-16 2003-07-16 Fremstillingaf polyketider og andre naturlige produkter DK1589031T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0216509A GB0216509D0 (en) 2002-07-16 2002-07-16 Production of polyketides and other natural products
GB0224922A GB0224922D0 (en) 2002-10-25 2002-10-25 Production of polyketides and other natural products
PCT/GB2003/003230 WO2004007709A2 (en) 2002-07-16 2003-07-16 Production of polyketides

Publications (1)

Publication Number Publication Date
DK1589031T3 true DK1589031T3 (da) 2007-12-10

Family

ID=30117119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05075774T DK1589031T3 (da) 2002-07-16 2003-07-16 Fremstillingaf polyketider og andre naturlige produkter

Country Status (15)

Country Link
US (7) US7300942B2 (enExample)
EP (5) EP2277898A3 (enExample)
JP (5) JP2005532809A (enExample)
CN (1) CN100569944C (enExample)
AT (1) ATE370161T1 (enExample)
AU (1) AU2003246965B2 (enExample)
BR (1) BR0312691A (enExample)
CA (1) CA2492153C (enExample)
CY (1) CY1107764T1 (enExample)
DE (1) DE60315723T2 (enExample)
DK (1) DK1589031T3 (enExample)
ES (2) ES2296063T3 (enExample)
MX (1) MXPA05000139A (enExample)
PT (1) PT1589031E (enExample)
WO (1) WO2004007709A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312691A (pt) * 2002-07-16 2005-05-10 Biotica Tech Ltd Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20050239178A1 (en) * 2004-04-27 2005-10-27 Wyeth Labeling of rapamycin using rapamycin-specific methylases
BRPI0511777A (pt) 2004-06-03 2008-01-15 Wyeth Corp complexo de meridamicina sintase, célula hospedeira, policetìdeo sintase sintética, seqüência de ácido nucleico, vetor recombinante, ácido nucleico isolado, construção de ácido nucleico quimérico, métodos para produzir um composto de policetìdeo e para determinar o requerimento estrutural da atividade de policetìdio, análogo de meridamicina, cepa de streptomyces mutante, ceto meridamicina c36 ou um sal farmaceuticamente aceitável da mesma, composto de desoximeridamicina, sais ou misturas farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, cepa de actinomiceto m507, e, métodos para produzir um macrolìdeo e para produzir um composto
GB0417852D0 (en) * 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
AR052269A1 (es) 2004-12-20 2007-03-07 Wyeth Corp Analogos de rapamicina, un proceso para su elaboracion y los usos de los mismos en la preparacion de un medicamento para el tratamiento de trastornos neurologicos, proliferativos e inflamatorios.
US20060182771A1 (en) 2005-02-09 2006-08-17 Dor Philippe J Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
CA2599547A1 (en) * 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
CN101836980A (zh) * 2005-03-11 2010-09-22 比奥蒂卡科技有限公司 39-去甲氧基雷帕霉素及其类似物的医药用途
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
KR100750810B1 (ko) 2006-08-07 2007-08-22 동국제약 주식회사 스트렙토마이세스 히그로스코피쿠스 atcc 14891변이주 및 이를 이용한 타크로리무스 생산 방법
DK2142638T3 (en) * 2007-04-02 2016-12-12 Newsouth Innovations Pty Ltd Process for the production of secondary metabolites
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US8921642B2 (en) * 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP2342335B1 (en) 2008-09-24 2015-09-16 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Novel gene cluster
GB0904540D0 (en) 2009-03-17 2009-04-29 Biotica Tech Ltd Novel compounds and methods for their production
GB0914589D0 (en) 2009-08-20 2009-09-30 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
WO2012076898A1 (en) 2010-12-08 2012-06-14 Oslo University Hospital Hf Triazole derivatives as wnt signaling pathway inhibitors
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2013107413A1 (zh) * 2012-01-19 2013-07-25 中国科学院上海巴斯德研究所 磷酸化途径相关因子在调控调节性t细胞功能中的应用
KR101331491B1 (ko) 2012-03-21 2013-11-20 이화여자대학교 산학협력단 증가된 라파마이신 생성능을 갖는 신규 미생물 균주
GB201312318D0 (en) 2013-07-09 2013-08-21 Isomerase Therapeutics Ltd Novel methods and compounds
WO2017040341A1 (en) * 2015-08-28 2017-03-09 Buck Institute For Research On Aging RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
AU2018219317A1 (en) 2017-02-10 2019-09-26 Mount Tam Therapeutics, Inc. Rapamycin analog
WO2019157363A2 (en) * 2018-02-09 2019-08-15 Mount Tam Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
WO2019157374A1 (en) * 2018-02-09 2019-08-15 Mount Tam Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of neurodegenerative conditions
IL315399A (en) 2019-01-22 2024-11-01 Aeovian Pharmaceuticals Inc Mtorc modulators and uses thereof
CN115125179B (zh) * 2021-03-26 2023-10-27 上海医药工业研究院 产雷帕霉素的基因工程菌及其应用
US20240376122A1 (en) * 2021-06-25 2024-11-14 Apertor Pharmaceuticals, Inc. Small molecule compounds
US20240350463A1 (en) * 2021-06-25 2024-10-24 Apertor Pharmaceuticals, Inc. Small molecule compounds

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
SE416705B (sv) 1978-02-27 1981-02-02 Torsten & Andersson Kaj Anordning for utskjutning av bollar
GB2165090A (en) 1984-09-26 1986-04-03 Philips Electronic Associated Improving the field distribution in high voltage semiconductor devices
JPS6453991A (en) 1987-08-25 1989-03-01 Mitsubishi Electric Corp Magazine-cum-reel
US5109112A (en) 1989-01-19 1992-04-28 Merck & Co., Inc. FK-506 cytosolic binding protein
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
WO1993013663A1 (en) 1992-01-17 1993-07-22 Abbott Laboratories Method of directing biosynthesis of specific polyketides
US5091389A (en) 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5093338A (en) 1991-04-23 1992-03-03 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
JPH06502659A (ja) 1991-05-31 1994-03-24 ファイザー インク 免疫抑制剤としてのラパマイシンプロドラッグの使用
US5763590A (en) 1991-10-11 1998-06-09 Vertex Pharmaceuticals, Inc. Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5498597A (en) 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
JP3140228B2 (ja) 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9302569D0 (en) 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
US5354845A (en) 1993-04-21 1994-10-11 Children's Research Institute FK-506 and rapamycin specific binding immunophilin
GB9315914D0 (en) 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン(マクロライド)の半合成類似体免疫調節剤
JP3745772B2 (ja) 1993-12-17 2006-02-15 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤として有用なラパマイシン誘導体
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
JP3226545B2 (ja) 1995-06-09 2001-11-05 ノバルティス・アクチエンゲゼルシャフト ラパマイシン誘導体
EP1493814A1 (en) 1995-07-06 2005-01-05 The Leland Stanford Junior University Cell-free synthesis of polyketides
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9710962D0 (en) 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
SK182498A3 (en) 1996-07-05 2000-05-16 Biotica Tech Ltd Erythromycins and process for their preparation
ES2182112T3 (es) 1996-07-30 2003-03-01 Novartis Ag Composiciones farmaceuticas para el tratamiento del rechazo de transplantes y de estados autoinmunes o inflamatorios, que comprenden ciclosporina a y 40-o-(2-hidroxietil)-rapamicina.
AU4246197A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
JP2001518784A (ja) * 1997-04-09 2001-10-16 アイソテクニカ,インコーポレイテッド ラパマイシンの特異的部位に対する抗体の産生方法
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
AU4549999A (en) * 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses
GB9814006D0 (en) 1998-06-29 1998-08-26 Biotica Tech Ltd Polyketides and their synthesis
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
US6150513A (en) 1998-09-16 2000-11-21 Kosan Biosciences, Inc. Polyketide synthase enzymes and recombinant DNA constructs therefor
ATE346938T1 (de) * 1998-10-02 2006-12-15 Kosan Biosciences Inc Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
SE516023C2 (sv) 1999-06-24 2001-11-12 Abb Ab Industrirobot innefattande en växellådskonfiguration samt förfarande i en industrirobot
JP2003504330A (ja) 1999-07-09 2003-02-04 オレゴン ヘルス アンド サイエンス ユニバーシティー 神経再生を促進するための組成物および方法
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
DE60033965T2 (de) 1999-10-29 2008-01-10 Kosan Biosciences, Inc., Hayward Rapamycin analoge
CA2405958C (en) 2000-04-13 2011-08-09 Biotica Technology Limited Hybrid glycosylated products and their production and use
WO2001087884A2 (en) * 2000-05-17 2001-11-22 Kosan Biosciences, Inc. Polyketide derivatives
GB0019986D0 (en) 2000-08-14 2000-10-04 Biotica Tech Ltd Polyketides and their synthesis
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
GB0128680D0 (en) 2001-11-29 2002-01-23 Biotica Tech Ltd Hybrid glycosylated products and their production and use
ES2485841T3 (es) * 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
BR0312691A (pt) 2002-07-16 2005-05-10 Biotica Tech Ltd Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo
CA2621093A1 (en) 2002-07-16 2004-01-22 Biotica Technology Limited Production of polyketides and other natural products
AU2007237187B2 (en) 2002-07-16 2010-08-05 Biotica Technology Limited Production of polyketides
GB0216509D0 (en) 2002-07-16 2002-08-28 Biotica Tech Ltd Production of polyketides and other natural products

Also Published As

Publication number Publication date
US20150266896A1 (en) 2015-09-24
US7390895B2 (en) 2008-06-24
US9040259B2 (en) 2015-05-26
US9605001B2 (en) 2017-03-28
US7300942B2 (en) 2007-11-27
EP1589031B1 (en) 2007-08-15
US7645768B2 (en) 2010-01-12
ES2544624T3 (es) 2015-09-02
EP1589031A3 (en) 2005-11-02
EP2277898A3 (en) 2011-06-01
JP2014176384A (ja) 2014-09-25
EP1655372A2 (en) 2006-05-10
EP1521828B1 (en) 2015-07-01
US20080287482A1 (en) 2008-11-20
WO2004007709A2 (en) 2004-01-22
US20060078980A1 (en) 2006-04-13
JP2008200039A (ja) 2008-09-04
EP2277898A2 (en) 2011-01-26
DE60315723D1 (de) 2007-09-27
PT1589031E (pt) 2007-11-28
US20080021211A1 (en) 2008-01-24
US20050272132A1 (en) 2005-12-08
DE60315723T2 (de) 2008-06-19
JP2005532809A (ja) 2005-11-04
AU2003246965A1 (en) 2004-02-02
CA2492153A1 (en) 2004-01-22
EP1589031A2 (en) 2005-10-26
HK1077845A1 (zh) 2006-02-24
JP4751899B2 (ja) 2011-08-17
JP2008194041A (ja) 2008-08-28
CY1107764T1 (el) 2013-04-18
MXPA05000139A (es) 2005-04-11
EP1521828A2 (en) 2005-04-13
EP1655372A3 (en) 2008-01-16
CN100569944C (zh) 2009-12-16
JP2010075187A (ja) 2010-04-08
ES2296063T3 (es) 2008-04-16
BR0312691A (pt) 2005-05-10
EP1967520A2 (en) 2008-09-10
CN1668741A (zh) 2005-09-14
AU2003246965B2 (en) 2008-05-15
US20110165633A1 (en) 2011-07-07
ATE370161T1 (de) 2007-09-15
US20080039486A1 (en) 2008-02-14
WO2004007709A3 (en) 2004-10-07
CA2492153C (en) 2012-05-08

Similar Documents

Publication Publication Date Title
DK1589031T3 (da) Fremstillingaf polyketider og andre naturlige produkter
Davis et al. Directing evolution: the next revolution in drug discovery?
Yang et al. Generation of an artificial double promoter for protein expression in Bacillus subtilis through a promoter trap system
WO2003066818A3 (en) Secretion, transcription and sporulation genes in bacillus clausii
NO20075088L (no) Vertscelle omfattende en vektor for fremstilling av proteiner som krever gamma-karboksylering
Choi et al. Enhanced production of recombinant proteins with Corynebacterium glutamicum by deletion of insertion sequences (IS elements)
ATE361286T1 (de) Borrelidin-derivate und ihre medizinische anwendung
WO2006136831A3 (en) Gene expression technique
JPWO2021100640A5 (enExample)
WO2020247803A2 (en) Frameshift suppressor trna compositions and methods of use
Kwon et al. Non‐natural amino acids for protein engineering and new protein chemistries
WO2004024898A3 (en) Nematode fatty acid desaturase-like sequences
NO20025146L (no) Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav
Pavlik et al. Arginine 58 is indispensable for proper function of the Francisella tularensis subsp. holarctica FSC200 HU protein, and its substitution alters virulence and mediates immunity against wild-type strain
Ma et al. Dissecting the catalytic and substrate binding activity of a class II lanthipeptide synthetase BovM
WO2005093069A3 (en) Production of mersacidin and its variants in sigh and/or mrsa negative bacillus host cells
Zhang et al. Construction of an expression vector that uses the aph promoter for protein expression in Corynebacterium glutamicum
Mishra et al. Crystallization and X-ray diffraction analysis of SpaE, a basal pilus protein from the gut-adapted Lactobacillus rhamnosus GG
CN116790566A (zh) 一种具有新的碱基编辑功能的核酸酶及编辑系统
EP1321517A3 (en) Gluconobacter oxydans 2-ketoreductase enzyme and applications thereof
ATE495245T1 (de) Verbesserte proteinexpression in bacillus subtilis
Mikhailov et al. Dual stoichiometry and subunit organization in the ClpP1/P2 protease from the cyanobacterium Synechococcus elongatus
Thompson et al. Characterization of an ECF56-family sigma factor from Streptomyces venezuelae reveals a highly conserved regulome
Zhu et al. An atypical GdpP enzyme linking cyclic nucleotide metabolism to
DK1461437T3 (da) Ekspressionsvektorer og promotorer til heterolog genekspression